[go: up one dir, main page]

MA32057B1 - Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique - Google Patents

Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique

Info

Publication number
MA32057B1
MA32057B1 MA33055A MA33055A MA32057B1 MA 32057 B1 MA32057 B1 MA 32057B1 MA 33055 A MA33055 A MA 33055A MA 33055 A MA33055 A MA 33055A MA 32057 B1 MA32057 B1 MA 32057B1
Authority
MA
Morocco
Prior art keywords
group
alkyl
optionally substituted
alkoxy
atom
Prior art date
Application number
MA33055A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-François Peyronel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32057(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32057B1 publication Critical patent/MA32057B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Composés de formule (i) dans laquelle: x et y forment avec l'atome d'azote qui les porte une aminé cyclique mono ou bicyclique saturée ou partiellement saturée, de 5 à 10 chainons comportant éventuellement 1 à 2 hétéroatomes supplémentaires choisis parmi o, s, n, éventuellement substituée par un atome d'halogène, un groupe (c1-c6)alkyle, un groupe (c1-c6)alcoxy, cyano, nrarb, coor8, les groupes (c1-c6)alkyle et (c1-c6)alcoxy étant éventuellement substitués par un ou plusieurs atomes d'halogène; r1 représente un atome d'hydrogène, un atome d'halogène, un groupe (c1-c6)alcoxy, un groupe (c1-c6)alkyle; r2 représente un atome d'hydrogène, un groupe (c1-c6)alkyle éventuellement substitué; un groupe (c1-c6)alcoxy éventuellement substitué; un groupe (c2-c6)alcényle, un groupe (c2-c6)alcynyle, un groupe -co-r5, un groupe -co-nr6r7, un groupe -co-o-r8, un groupe -nr9-co-r10, un groupe -n=ch-nrarb, un atome d'halogène, un groupe cyano, nitro, hydroxyiminoalkyle, alcoxyiminoalkyle, un groupe (c1-c6)alkylthio, un groupe (c1-c6)alkylsulfinyle, un groupe (c1-c6)alkylsulfonyle, un groupe (((c1-c6)alkyl)3)silyléthynyle, un groupe -so2-nr9r10, un groupe phényle éventuellement substitué, un groupe hétérocyclique éventuellement substituée; r3 représente un atome d'hydrogène, un groupe (c2-c6)alkyle, un groupe (c1-c6)alcoxy ou un atome d'halogène, r4 représente un atome d'hydrogène, un groupe (c1-c4)alkyle, un groupe (c1-c4)alcoxy ou un atome de fluor, à l'état de base ou de sel d'addition à un acide. Utilisation en thérapeutique.
MA33055A 2008-01-02 2010-08-02 Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique MA32057B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0800004A FR2925902B1 (fr) 2008-01-02 2008-01-02 DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
PCT/FR2008/001835 WO2009112651A1 (fr) 2008-01-02 2008-12-31 Dérivés d'mtoazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
MA32057B1 true MA32057B1 (fr) 2011-02-01

Family

ID=39739369

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33055A MA32057B1 (fr) 2008-01-02 2010-08-02 Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique

Country Status (21)

Country Link
US (1) US20100317656A1 (fr)
EP (1) EP2225244A1 (fr)
JP (1) JP2011508759A (fr)
KR (1) KR20100109941A (fr)
CN (1) CN101959886A (fr)
AR (1) AR070073A1 (fr)
AU (1) AU2008352728A1 (fr)
BR (1) BRPI0822223A2 (fr)
CA (1) CA2710797A1 (fr)
CL (1) CL2008003927A1 (fr)
CO (1) CO6331307A2 (fr)
EA (1) EA201070817A1 (fr)
FR (1) FR2925902B1 (fr)
IL (1) IL206673A0 (fr)
MA (1) MA32057B1 (fr)
MX (1) MX2010007351A (fr)
PA (1) PA8810101A1 (fr)
PE (1) PE20091182A1 (fr)
TW (1) TW200932746A (fr)
UY (1) UY31588A1 (fr)
WO (1) WO2009112651A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2925907B1 (fr) * 2008-01-02 2010-10-15 Sanofi Aventis DERIVES DE 2-HETEROAROYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
PL2610255T3 (pl) * 2010-08-25 2016-08-31 Neopharm Co Ltd Związki 1H-benzo[d]imidazol-5-ilowe i kompozycja do leczenia chorób zapalnych
WO2016133838A1 (fr) 2015-02-20 2016-08-25 Rigel Pharmaceuticals, Inc. Inhibiteurs du gdf 8
US11833156B2 (en) 2017-09-22 2023-12-05 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
WO2019077631A1 (fr) 2017-10-18 2019-04-25 Jubilant Biosys Limited Composés imidazo-pyridine à utiliser en tant qu'inhibiteurs de pad
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
CN107915752B (zh) * 2017-11-14 2018-09-18 牡丹江医学院 一种治疗白内障的药物及其制备方法
BR112020010322A2 (pt) 2017-11-24 2020-11-17 Jubilant Episcribe Llc composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827189D0 (en) * 1988-11-21 1988-12-29 Fujisawa Pharmaceutical Co 2(1h)-quinolinone compounds processes for preparation thereof & pharmaceutical composition comprising same
US5716964A (en) * 1989-12-04 1998-02-10 G.D. Searle & Co. Tetrazolyl substituted imidazo 1,2-a!pyridinylalkyl compounds for treatment of neurotoxic injury
FR2696177B1 (fr) * 1992-09-28 1995-05-12 Synthelabo Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
GB0420519D0 (en) * 2004-09-15 2004-10-20 Novartis Ag Organic compounds
WO2009023179A2 (fr) * 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Entités chimiques bicycliques azotées pour traiter les infections virales
WO2009086303A2 (fr) * 2007-12-21 2009-07-09 University Of Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes

Also Published As

Publication number Publication date
EP2225244A1 (fr) 2010-09-08
EA201070817A1 (ru) 2011-02-28
IL206673A0 (en) 2010-12-30
FR2925902A1 (fr) 2009-07-03
CL2008003927A1 (es) 2010-02-12
AR070073A1 (es) 2010-03-10
UY31588A1 (es) 2009-08-03
KR20100109941A (ko) 2010-10-11
CN101959886A (zh) 2011-01-26
PA8810101A1 (es) 2009-08-26
MX2010007351A (es) 2010-10-05
FR2925902B1 (fr) 2011-01-07
AU2008352728A1 (en) 2009-09-17
CA2710797A1 (fr) 2009-09-17
WO2009112651A1 (fr) 2009-09-17
CO6331307A2 (es) 2011-10-20
BRPI0822223A2 (pt) 2015-06-23
JP2011508759A (ja) 2011-03-17
TW200932746A (en) 2009-08-01
US20100317656A1 (en) 2010-12-16
PE20091182A1 (es) 2009-08-31

Similar Documents

Publication Publication Date Title
MA32057B1 (fr) Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique
FR2926554B1 (fr) Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
MA32248B1 (fr) Dérivés polysubstitues de 6-heteroaryle-imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique
MA30792B1 (fr) DERIVES DE 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
MA28098A1 (fr) Derives de n-[phenyl ( pyrrolidin-2-yl ) methyl] benzamide et n-[(azepan-2-yl) phenylmethyl] benzamide, leur preparation et leur application en therapeutique
RU2008107727A (ru) Макроциклические ингибиторы вируса гепатита с
MA27390A1 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
TN2011000569A1 (fr) Derives de cyclopenta[c]pyrrole-2-carboxylates, leur preparation et leur application en therapeutique
CA2656716C (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
MA33893B1 (fr) Derives de diphenyl-pyrazolopyridines,leur preparation et leur appalication en therapeutique
MA28097A1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl] benzamide, leur preparation et leur application en therapeutique
MA32088B1 (fr) Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique
CY1110014T1 (el) Παραγωγα τετραϋδροκαρβαζολιου χρησιμα ως τροποποιητες υποδοχεα ανδρογονων (sarm)
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
EA200700099A1 (ru) Производные пиридина
MA32098B1 (fr) Dérivés d'urée de tetrahydroquinoxaline, leur préparation et leur application en thérapeutique
FR2854633A1 (fr) Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
BR0206561A (pt) Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
RU2009144538A (ru) Новые циклические пептидные соединения
MA32059B1 (fr) Dérivés de n-heterocyclique-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
RU2013136895A (ru) Новое бициклическое соединение или его соль
RU2011146641A (ru) Производные имидазолидин-2,4-диона и их применение в качестве лекарственного средства против рака
MA33320B1 (fr) Derives de rifamycine